Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Yuzhong, Chongqing 400016, P.R. China.
Department of Orthopedics, People's Hosipital of Leshan, Leshan, Sichuan 614000, P.R. China.
Int J Oncol. 2017 Nov;51(5):1427-1438. doi: 10.3892/ijo.2017.4136. Epub 2017 Sep 27.
The present study was performed to establish and characterize new human osteosarcoma cell lines resistant to pyropheophorbide-α methyl ester‑mediated photodynamic therapy (MPPa-PDT). MPPa-PDT-resistant cells are isolated from the human osteosarcoma MG63 and HOS cell lines and two resistant populations were finally acquired, including MG63/PDT and HOS/PDT. Cell Counting Kit-8 (CCK-8) assay was used to determine the MPPa-PDT, cisplatin (CDDP) resistance and proliferation of MG63, MG63/PDT, HOS and HOS/PDT cells. The intracellular ROS were analyzed using DCFH-DA staining. The colony formation, invasion and migration of parental and resistant cells were compared. FCM was employed to examine the cell cycle distribution, the apoptosis rate and the proportion of CD133+ cells. The fluorescence intensity of intracellular MPPa was observed by fluorescence microscopy and quantified using microplate reader. The protein levels were assessed by western blotting (WB). Compared with two parental cells, MG63/PDT and HOS/PDT were 1.67- and 1.61-fold resistant to MPPa-PDT, respectively, and also exhibited the resistance to CDDP. FCM assays confirmed that both MG63/PDT and HOS/PDT cells treated with MPPa-PDT displayed a significantly lower apoptosis rate in comparison with their corresponding parental cells. The expression of apoptosis-related proteins (i.e. cleaved-caspase 3 and cleaved‑PARP), intracellular ROS and the antioxidant proteins (HO-1 and SOD1) in MG63/PDT and HOS/PDT cells was also lower than that in parental cells. Both MG63/PDT and HOS/PDT cells exhibited changes in proliferation, photosensitizer absorption, colony formation, invasion, migration and the cell cycle distribution as compared to MG63 and HOS cells, respectively. Compared to MG63 and HOS cells, both resistant cell lines had a higher expression of CD133, survivin, Bcl-xL, Bcl-2, MRP1, MDR1 and ABCG2, but a lower expression of Bax. The present study successfully established two resistant human osteosarcoma cell lines which are valuable to explore the resistance-related mechanisms and the approaches to overcome resistance.
本研究旨在建立并鉴定对原卟啉 IX 甲酯介导的光动力疗法(MPPa-PDT)耐药的新型人骨肉瘤细胞系。耐药细胞系是从人骨肉瘤 MG63 和 HOS 细胞系中分离出来的,最终获得了两个耐药群体,包括 MG63/PDT 和 HOS/PDT。通过细胞计数试剂盒-8(CCK-8)测定法确定 MPPa-PDT、顺铂(CDDP)耐药性和 MG63、MG63/PDT、HOS 和 HOS/PDT 细胞的增殖能力。使用 DCFH-DA 染色分析细胞内 ROS。比较亲本细胞和耐药细胞的集落形成、侵袭和迁移能力。FCM 用于检查细胞周期分布、凋亡率和 CD133+细胞的比例。通过荧光显微镜观察细胞内 MPPa 的荧光强度,并使用微孔板读数器定量。通过 Western blot(WB)评估蛋白水平。与两个亲本细胞相比,MG63/PDT 和 HOS/PDT 对 MPPa-PDT 的耐药性分别提高了 1.67-和 1.61 倍,并且对 CDDP 也表现出耐药性。FCM 检测证实,与相应的亲本细胞相比,经 MPPa-PDT 处理的 MG63/PDT 和 HOS/PDT 细胞的凋亡率明显降低。MG63/PDT 和 HOS/PDT 细胞中凋亡相关蛋白(即 cleaved-caspase 3 和 cleaved-PARP)、细胞内 ROS 和抗氧化蛋白(HO-1 和 SOD1)的表达也低于亲本细胞。与 MG63 和 HOS 细胞相比,MG63/PDT 和 HOS/PDT 细胞的增殖、光敏剂吸收、集落形成、侵袭、迁移和细胞周期分布均发生变化。与 MG63 和 HOS 细胞相比,两个耐药细胞系的 CD133、survivin、Bcl-xL、Bcl-2、MRP1、MDR1 和 ABCG2 的表达均升高,而 Bax 的表达降低。本研究成功建立了两种耐药的人骨肉瘤细胞系,这对于探讨耐药相关机制和克服耐药的方法具有重要价值。